Showcasing Development & Advantages of RB-601: A First-in-Class c-MET/EGFR Bispecific Nano ADC
12:00 pm - Monday 23rd February 2026
- Undergoing development of RB-601, a bispecific nano ADC
- Highlighting RRB-601 advantages against classical bispecific ADCs across tumour tissue penetration, improved anti-tumour activity and superior tolerability profile
- Exploring ongoing biomarker and clinical trial with potential across solid tumour indications
